The United States Patent Office (USPTO) approved another patent for the innovative design used in Stratedigm’s Flow Cytometers. The latest patent issued by the USPTO covers Stratedigm’s unique dynamic seal technology which in addition to offering users the easiest and most ergonomic way to insert test tubes in a cytometer, also improves reliability, serviceability, and manufacturability of pressure driven analyzers. The adaptive design of Stratedigm’s dynamic seal allows for a friction-free sample tube injection and removal, making Stratedigm’s cytometers compatible with a range of lower cost sample tubes manufactured by a variety of vendors. “Stratedigm’s continued success with expanding its intellectual property portfolio used in the commercialization of its compact, scalable (up to 4 lasers and 14 colors) and high performance analyzers are further enhanced by the USPTO’s latest grant of broad coverage to our Dynamic Seal Design. We expect similar success with our full portfolio of pending patents in the upcoming years,” noted Shervin Javadi, Stratedigm’s CEO.
Stratedigm’s S1000 analyzer was launched on May of 2008 at ISAC. The company’s wide range of products has since been adopted by prestigious core labs and private and government research facilities around the nation. The design of Stratedigm’s cytometers are based on multiple, patented and patent pending technologies covering their unique and powerful excitation optics, emission optics, fluidics architecture and hybrid electronics creating a product with industry-leading sensitivity and unparalleled manufacturability and reliability.